Metronidazol Fresenius (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radicals. These radicals interact with DNA, causing strand breakage and inhibiting nucleic acid synthesis, which leads to bacterial or protozoal cell death while sparing most human cells.

The specific dose of Metronidazol Fresenius is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate regimen for each individual case.

Safety data for metronidazole in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as metronidazole can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazol Fresenius belongs to the nitroimidazole class, which is uniquely effective against anaerobic bacteria and certain protozoa. Unlike many broad‑spectrum antibiotics, it targets organisms that thrive in low‑oxygen environments, making it the preferred choice for infections where anaerobes predominate, such as intra‑abdominal sepsis.

Metronidazol Fresenius should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintain the product in its original packaging until use to preserve stability and potency.

The product is supplied as an intravenous solution and is administered by a healthcare professional through a vein, typically using a controlled infusion pump or syringe. Administration settings include hospitals, surgical centers, and other clinical environments where sterile IV delivery is ensured.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and rare skin conditions like Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, rash, or signs of hypersensitivity, and therapy should be discontinued if severe reactions occur.

Patients with known hypersensitivity to metronidazole or other nitroimidazoles should avoid the product. Caution is also advised for individuals with severe hepatic or renal impairment, and those who consume alcohol during therapy due to the risk of a disulfiram‑like reaction.